LB6V — A Major Step Toward Protecting Against Lyme Disease
The most advanced Lyme disease vaccine candidate shows strong efficacy in Phase 3 trials, with more than 70% protection against confirmed Lyme disease.
Pump.fun Coin — Contract Address
Community-launched memecoin on Pump.fun. Not affiliated with Pfizer, Valneva, or this informational site. Always do your own research before interacting with any token.
AqUX2uCabsKjGMoZr3bFiJzaBWhBRaCRvvyoFgSCpumpCryptocurrency is highly volatile. This is not financial advice. The token is independent of the LB6V vaccine program.
What is Lyme Disease?
Lyme disease is caused by Borrelia bacteria transmitted through the bite of infected blacklegged ticks. It affects an estimated hundreds of thousands of people annually across the United States and Europe and is the most common vector-borne illness in the Northern Hemisphere.
Early symptoms can include fever, fatigue, and a characteristic rash. If left untreated, infection can lead to serious complications affecting the joints, heart, and nervous system.
Introducing LB6V (PF-07307405)
Formerly known as VLA15, LB6V is being developed in partnership between Pfizer and Valneva as the first vaccine candidate to address all six major Lyme disease–causing serotypes.
6-Valent OspA Vaccine
Recombinant protein vaccine targeting the 6 most common Borrelia serotypes across North America and Europe.
Ages 5 and Older
Designed for children and adults aged 5 years and above living in or visiting endemic areas.
Most Advanced Candidate
Currently no Lyme disease vaccines are approved. LB6V is the most advanced candidate in late-stage development.
Strong Efficacy. Well Tolerated.
Announced March 23, 2026 — the VALOR ("Vaccine Against Lyme for Outdoor Recreationists") trial enrolled thousands of participants across endemic regions in the U.S., Canada, and Europe.
vaccine efficacy from 28 days after dose 4 in preventing confirmed Lyme disease.
efficacy measured from 1 day after dose 4 — protection begins quickly.
"These Phase 3 results mark a significant milestone in our shared mission to help prevent Lyme disease, a serious and growing public health threat."
"We are proud to bring forward a vaccine candidate that could help protect millions of people at risk of Lyme disease across the Northern Hemisphere."
How LB6V Works
LB6V targets Outer Surface Protein A (OspA), a protein expressed by Borrelia bacteria while they reside inside the tick. By generating antibodies against OspA, the vaccine intercepts the bacteria before they ever reach the human bloodstream.
Explore the mechanism
Protection for People Who Love the Outdoors
- Hikers, campers, and trail runners
- Outdoor workers — foresters, landscapers, park rangers
- Families living in or visiting endemic regions
- Children aged 5 and older
- Travelers to high-risk areas in peak tick season
Pfizer and Valneva Announce Positive Phase 3 Results
March 23, 2026 — Pfizer and Valneva announced that the Phase 3 VALOR trial of LB6V met its primary efficacy endpoint, with regulatory submissions being planned.
Talk to your doctor about Lyme disease prevention
Sign up to be notified when LB6V regulatory updates and availability information are announced.
Investigational vaccine. Not approved by regulatory authorities. Informational purposes only — not medical advice.